Rapid antigen tests have become a critical tool to detect COVID-19 in people who are infectious — allowing those who need to quarantine to do so, and those who don’t, to continue to do the things they love.
BinaxNOW has become America's leading rapid antigen test, trusted by tens of thousands of schools and universities, long-term care facilities and nursing homes, workplaces, state testing programs and millions of families.
As the developers of BinaxNOW, we have deep history in healthcare and know the importance of having the data and science to back technologies. In addition to our research, leading academic institutions have conducted research and showed BinaxNOW is effective at detecting the virus — including Omicron and other variants of concern — and remains an essential tool to the world’s COVID-19 response.
Here's the latest research on rapid antigen tests in general and on BinaxNOW specifically:
University of California San Francisco — Omicron Detection
A real-world study from the University of California San Francisco showed BinaxNOW can detect the Omicron variant in the vast majority of people who are infected and carrying high levels of the virus.
- Study conducted via a walk-up community testing site in San Francisco
- 731 participants
- Simultaneous nasal rapid antigen testing (BinaxNOW) and PCR testing was performed
- A single BinaxNOW rapid antigen test detected 95% of high viral load omicron cases